In a turbulent market environment, agilon health (AGL) stock has reached a 52-week low, trading at $3.06. This significant downturn reflects a stark contrast from its previous performance, with the company's shares experiencing a precipitous decline of -81.28% over the past year. Investors are closely monitoring AGL as it navigates through the current economic headwinds, which have severely impacted its market valuation and investor confidence. The healthcare sector, in which agilon health operates, has faced numerous challenges, and AGL's recent price level underscores the broader industry's volatility and the company's struggles within this context.
In other recent news, agilon health Inc (NYSE:AGL). experienced a revenue shortfall in its second-quarter earnings report, leading Deutsche Bank to reduce the company's price target from $5.00 to $4.00. The company's total revenue was reported at $1.48 billion, a 38% increase year-over-year, but below the consensus estimate of $1.56 billion. Despite this, agilon health reported better-than-expected adjusted EBITDA figures, with a loss of $2.8 million compared to the anticipated $7.9 million loss forecasted by analysts.
The company's Medicare Advantage membership grew by 38% year-over-year to 513,000, aligning with the lower end of the guidance range. However, revenue was impacted by retroactive contract cancellations which did not affect the medical margin. Despite these challenges, the company remains focused on growth and efficiency, implementing a new data lake, which resulted in an 8% reduction in ER and inpatient admissions.
During the company's second-quarter earnings call, CEO Steve Sell announced adjustments to full-year guidance due to these recent developments. The company lowered its full-year revenue guidance due to retroactive contract terminations, but maintained its full-year medical margin guidance at $400 million to $450 million. Looking forward, agilon health expects to be free cash flow positive starting in 2026.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on agilon health's (AGL) current financial situation. Despite the company's significant revenue growth of 65.62% over the last twelve months, AGL is not profitable, with an operating income margin of -4.75%. This aligns with an InvestingPro Tip indicating that analysts do not anticipate the company will be profitable this year.
The market's pessimism is further reflected in AGL's valuation metrics. With a P/E ratio of -7.04 and a market cap of $1.29 billion, the stock is trading at a low revenue valuation multiple. This could potentially present an opportunity for investors, especially considering that the InvestingPro Fair Value estimate stands at $5.02, significantly higher than the current trading price.
However, investors should approach with caution. An InvestingPro Tip highlights that AGL suffers from weak gross profit margins, which is evident in the reported gross profit margin of just 0.93% for the last twelve months. This weakness in profitability may explain why 5 analysts have revised their earnings downwards for the upcoming period, as noted in another InvestingPro Tip.
For those considering AGL's potential, it's worth noting that InvestingPro offers 8 additional tips for this stock, providing a more comprehensive analysis for informed decision-making.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.